Sun, Fumou
Cheng, Yan https://orcid.org/0000-0001-7877-9622
Wanchai, Visanu https://orcid.org/0000-0003-2243-3838
Guo, Wancheng
Mery, David
Xu, Hongwei
Gai, Dongzheng
Siegel, Eric https://orcid.org/0000-0001-9824-6612
Bailey, Clyde
Ashby, Cody https://orcid.org/0000-0002-9361-0283
Al Hadidi, Samer https://orcid.org/0000-0003-4297-8042
Schinke, Carolina https://orcid.org/0000-0002-2699-1741
Thanendrarajan, Sharmilan
Ma, Yupo
Yi, Qing https://orcid.org/0000-0003-1529-3398
Orlowski, Robert Z.
Zangari, Maurizio
van Rhee, Frits https://orcid.org/0000-0001-9959-1282
Janz, Siegfried https://orcid.org/0000-0002-2229-5511
Bishop, Gail https://orcid.org/0000-0002-1291-5078
Tricot, Guido
Shaughnessy, John D. Jr
Zhan, Fenghuang https://orcid.org/0000-0001-5417-2973
Funding for this research was provided by:
Foundation for the National Institutes of Health (1R01CA236814-01A1, 3R01-CA236814-03S1, U54CA272691-01, U54CA272691-01)
U.S. Department of Defense (CA180190, CA180190)
Myeloma Crowd Research Initiative Award, Paula and Rodger Riney Foundation, Myeloma Solution Fund, UAMS Winthrop P. Rockefeller Cancer Institute (WRCRI) Fund
Arkansas Breast Cancer Research Program
Article History
Received: 11 July 2023
Accepted: 9 January 2024
First Online: 19 January 2024
Competing interests
: F.S. and F.Z. are inventors on the patent application “Bispecific BCMA-CD24-CAR-T design”, describing the therapeutic use of BCMA-CD24-CAR-T cells for the treatment of multiple myeloma. The patent number is pending. The other authors declare no competing interests.